FDA wants race, ethnicity factored in administering COVID drugs

FDA wants race, ethnicity factored in administering COVID drugs


The Food and Drug Administration is urging health care providers to consider race or ethnicity as well as underlying medical conditions when classifying individuals as “high risk for progression to severe COVID-19″ and qualifying for antibody treatment. 

A fact sheet issued by the agency detailing the emergency use authorization of the drug sotrovimab for treatment of mild to moderate COVID-19 cases includes a list of medical conditions that may qualify patients for the treatment.

Those conditions include advanced age (65 or older), obesity, pregnancy, diabetes, cardiovascular disease, chronic lung disease, and neurodevelopmental disorders.

Trending: Vaccine mandates around the world collapse after U.S. Supreme Court decision

The document, which was last updated in December, also notes that “[o]ther medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for

Continue reading

You Might Like

 

Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Thanks for sharing!
Send this to a friend